AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9203245 — intervention group
Group type: COMPARATOR
Intervention: Remacemide hydrochloride
Number of subjects: 17
Study 7971537 — intervention group
Group type: EXPERIMENTAL
Intervention: Short advice by the physician (I)
Number of subjects: 46
Study 7971537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthy advice by the physician (III)
Number of subjects: 46
Study 7971537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred discussion (IV)
Number of subjects: 46
Study 7971537 — intervention group
Group type: EXPERIMENTAL
Intervention: Short question by the patient (II)
Number of subjects: 46
Study 3687203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention goals related to changing cardiovascular risk factors, morbidity, and subjective health
Number of subjects: 620
Study 3687203 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial and somatic factors
Number of subjects: 620
Study 29175541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough stress test with bladder filled to half functional capacity
Number of subjects: 140
Study 29175541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough stress tests (various positions and bladder volumes)
Number of subjects: 140
Study 29175541 — intervention group
Group type: COMPARATOR
Intervention: 24-hour pad test
Number of subjects: 140
Study 27553205 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose 2L-PEGA
Number of subjects: 198
Study 27553205 — intervention group
Group type: COMPARATOR
Intervention: Single-dose 4L-PEG
Number of subjects: 198
Study 27553205 — intervention group
Group type: COMPARATOR
Intervention: Split-dose 4L-PEG
Number of subjects: 198
Study 24105362 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention
Number of subjects: 31
Study 23376362 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFN) therapy for 52 weeks
Number of subjects: 210
Study 19963403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (ARTZ Dispo) 25 mg/wk for 5 weeks
Number of subjects: 51
Study 19963403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 51
Study 19963403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (ARTZ Dispo)
Number of subjects: 51
Study 18280580 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic Symptoms Inventory (SSI) assessment in patients with MDD
Number of subjects: 2191
Study 18280580 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Hamilton Depression Rating Scale (HAMD)
Number of subjects: 2191
Study 16905181 — intervention group
Group type: COMPARATOR
Intervention: High-risk cardiovascular prevention approach including complete registration of risk factors, optimization of medical treatment, and health counseling on high fat consumption, smoking, and physical inactivity.
Number of subjects: 1300
Study 16905181 — intervention group
Group type: COMPARATOR
Intervention: High-risk cardiovascular prevention approach
Number of subjects: 1300
Study 12815565 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 5010
Study 12815565 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010
Study 12815565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study 10657828 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-3 red blood cells stored for ≤42 days
Number of subjects: 54
Study 10657828 — intervention group
Group type: COMPARATOR
Intervention: Citrate, phosphate, dextrose, and adenine RBCs stored for ≤7 days
Number of subjects: 54
Study 9357453 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein cuff
Number of subjects: 261
Study 9357453 — intervention group
Group type: COMPARATOR
Intervention: No vein cuff
Number of subjects: 261
Study 8460758 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 5 mg.h-1
Number of subjects: 40
Study 8460758 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 10 mg.h-1
Number of subjects: 40
Study 8460758 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine at 1 mg.h-1 combined with ketamine at 20 mg.h-1
Number of subjects: 40
Study 8460758 — intervention group
Group type: COMPARATOR
Intervention: Morphine at 1 mg.h-1 alone
Number of subjects: 40
Study 3536521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP)
Number of subjects: 124
Study 3536521 — intervention group
Group type: COMPARATOR
Intervention: methysergide (M)
Number of subjects: 124
Study 31902378 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from flaxseed oil (2 × 1000 mg/d, containing 400 mg α-linolenic acid per capsule)
Number of subjects: 60
Study 31902378 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from flaxseed oil
Number of subjects: 60
Study 31902378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30998063 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training (CST)
Number of subjects: 179
Study 30998063 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced by HF education (HFE)
Number of subjects: 179
Study 27825572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice (30min, applied twice at 8h interval)
Number of subjects: 30
Study 27825572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold CO2 (2min, applied twice at 8h interval)
Number of subjects: 30
Study 27825572 — intervention group
Group type: COMPARATOR
Intervention: Contralateral non-treated knees (control group)
Number of subjects: 30
Study 26000667 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mL of 0.5% lidocaine (group L)
Number of subjects: 69
Study 26000667 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL of 0.5% lidocaine mixed with 80 mg (2 mL) of methylprednisolone acetate (group LS)
Number of subjects: 69
Study 26000667 — intervention group
Group type: COMPARATOR
Intervention: Both groups (L and LS)
Number of subjects: 69
Study 23433200 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic compound (seven bacterial species including Lactobacillus and Bifidobacterium strains and Streptococcus thermophiles)
Number of subjects: 180
Study 23433200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 23433200 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic compound
Number of subjects: 180
Study 23433200 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic compound and Placebo
Number of subjects: 180
Study 21840828 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly Purified Follicle Stimulating Hormone (HP-FSH)
Number of subjects: 0
Study 21840828 — intervention group
Group type: COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone (rFSH)
Number of subjects: 0
Study 19847725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural depression management training
Number of subjects: 75
Study 19847725 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation without management of depressive symptoms
Number of subjects: 75
Study 16696861 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy
Number of subjects: 0
Study 16696861 — intervention group
Group type: COMPARATOR
Intervention: Conventional unilateral transflaval discectomy
Number of subjects: 0
Study 14706955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 87
Study 14706955 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 87
Study 11231765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular hypertension patients
Number of subjects: 55
Study 11231765 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 55
Study 10095928 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to antibiotics
Number of subjects: 100
Study 10095928 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to various antibiotics
Number of subjects: 100
Study 10095928 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to gentamicin, streptomycin, chloramphenicol, tetracycline, trimethoprim, and sulfamethoxazole
Number of subjects: 100
Study 10095928 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to ampicillin, piperacillin, amikacin, streptomycin, chloramphenicol, tetracycline, trimethoprim, and sulfamethoxazole
Number of subjects: 100
Study 10095928 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli resistant to five or more antibiotics
Number of subjects: 100
Study 8001628 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 8001628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14621746 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (40 microg/kg twice a day, intravenously from day 1 to day 7)
Number of subjects: 45
Study 14621746 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 45
Study 14621746 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 45
Study 414280 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (1.5 g)
Number of subjects: 0
Study 414280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (200 mg)
Number of subjects: 0
Study 414280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 0
Study 414280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (200 mg) plus Ephedrine (50 mg)
Number of subjects: 0
Study 414280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30304481 — intervention group
Group type: EXPERIMENTAL
Intervention: PlateDesigner web-based application for randomization in microplate experiments
Number of subjects: 0
Study 30304481 — intervention group
Group type: EXPERIMENTAL
Intervention: PlateDesigner web-based application
Number of subjects: 0
Study 28679605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive ventilation (NIV) for three additional nights (n=61)
Number of subjects: 120
Study 28679605 — intervention group
Group type: COMPARATOR
Intervention: Direct NIV discontinuation (n=59)
Number of subjects: 120
Study 28679605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal NIV for three additional nights (n=61)
Number of subjects: 120
Study 26118825 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every-other-week
Number of subjects: 147
Study 26118825 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg every-other-week
Number of subjects: 147
Study 26118825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation to 80 mg every-other-week for patients with suboptimal response to 40 mg
Number of subjects: 147
Study 26118825 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (both doses)
Number of subjects: 147
Study 23865389 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c concentration
Number of subjects: 2270
Study 23865389 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 2270
Study 23865389 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HbA1c of one percentage point
Number of subjects: 2270
Study 23865389 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c of 37 mmol/mol (5.5%)
Number of subjects: 2270
Study 21717822 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/day for 12 weeks
Number of subjects: 54
Study 21717822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19400885 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% salicylic acid peels followed by three 30% salicylic acid peels
Number of subjects: 10
Study 19400885 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the face)
Number of subjects: 10
Study 16766971 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ITD (‐7 cmH2O)
Number of subjects: 8
Study 16766971 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD (0 cmH2O)
Number of subjects: 8
Study 15867711 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable absorbent body-worn products (Paddy T)
Number of subjects: 14
Study 15867711 — intervention group
Group type: COMPARATOR
Intervention: Disposable all-in-one product
Number of subjects: 14
Study 15867711 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable products (other than Paddy T)
Number of subjects: 14
Study 11166969 — intervention group
Group type: EXPERIMENTAL
Intervention: MST (oral retarded morphine sulphate)
Number of subjects: 12
Study 11166969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11166969 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 12
Study 9731991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole in combination with antibiotics (amoxicillin, clarithromycin, metronidazole, or tinidazole)
Number of subjects: 0
Study 9731991 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy including lansoprazole
Number of subjects: 0
Study 9731991 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole vs. other PPIs (e.g., omeprazole)
Number of subjects: 0
Study 7987362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (4 g/day for 14 days)
Number of subjects: 8
Study 7987362 — intervention group
Group type: COMPARATOR
Intervention: Control I (CON I, Day 0)
Number of subjects: 8
Study 7987362 — intervention group
Group type: COMPARATOR
Intervention: Control II (CON II, Day 14)
Number of subjects: 8
Study 7987362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (L-CN, Day 28)
Number of subjects: 8
Study 2660640 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (15 micrograms.kg‐1)
Number of subjects: 40
Study 2660640 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (45 micrograms.kg‐1)
Number of subjects: 40
Study 31162757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training (clamping urinary catheters at 4-hr intervals and leaving them open for 5 min on the second postoperative day)
Number of subjects: 50
Study 31162757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 50
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamycin
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam plus amoxicillin-clavulanic acid
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin plus ampicillin plus amoxicillin
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 7169
Study 31633844 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 7169
Study 28789712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 422
Study 28789712 — intervention group
Group type: COMPARATOR
Intervention: Micronutrient powder (MNP)
Number of subjects: 422
Study 25105727 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep (5 hr time in bed)
Number of subjects: 12
Study 25105727 — intervention group
Group type: COMPARATOR
Intervention: Long sleep (9 hr time in bed)
Number of subjects: 12
Study 23782590 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + SWT (Treatment As Usual + Structured Writing Therapy)
Number of subjects: 34
Study 23782590 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment As Usual)
Number of subjects: 34
Study 20479668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg plus normal saline infiltration (G)
Number of subjects: 43
Study 20479668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg plus 2% lidocaine infiltration (GL)
Number of subjects: 43
Study 20479668 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo plus 2% lidocaine infiltration (L)
Number of subjects: 43
Study 20479668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gabapentin 900 mg (G)
Number of subjects: 43
Study 18462650 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 137
Study 18462650 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 137
Study 16986593 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14656787 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask at 5 L*min(‐1)
Number of subjects: 0
Study 14656787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mike Cannula at 5 L*min(‐1)
Number of subjects: 0
Study 14656787 — intervention group
Group type: EXPERIMENTAL
Intervention: OxyArm
Number of subjects: 0
Study 14656787 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 0
Study 11448573 — intervention group
Group type: EXPERIMENTAL
Intervention: CR (20.0 g of CR/d for 7 d followed by 10.0 g of CR/d for 14 d)
Number of subjects: 40
Study 11448573 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3.0 g of HMB/d)
Number of subjects: 40
Study 11448573 — intervention group
Group type: EXPERIMENTAL
Intervention: CR/HMB (CR and HMB combined)
Number of subjects: 40
Study 11448573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9756248 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamfenfluramine (d‐fen)
Number of subjects: 31
Study 9756248 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 7804510 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (U) - bolus of 25 mg; initial infusion rate of 15-85 micrograms/kg/min; maintenance infusion rate of 2-7 micrograms/kg/min
Number of subjects: 53
Study 7804510 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (S) - initial infusion rate of 1-2 micrograms/kg/min; maintenance infusion rate of max. 5 micrograms/kg/min
Number of subjects: 53
Study 2967917 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 59
Study 2967917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2967917 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (in high-risk subset)
Number of subjects: 59
Study 30189012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone (5/2.5 or 10/5 mg) during haemodialysis
Number of subjects: 9
Study 30189012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone (5/2.5 or 10/5 mg) between haemodialysis sessions
Number of subjects: 9
Study 27973690 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading after implant placement (N = 81, group A)
Number of subjects: 158
Study 27973690 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading after three months (N = 77, group B)
Number of subjects: 158
Study 27973690 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading protocol
Number of subjects: 158
Study 26699193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine pressure (IUP) measured in Montevideo units (MU)
Number of subjects: 503
Study 26699193 — intervention group
Group type: EXPERIMENTAL
Intervention: IUP < 100 MU
Number of subjects: 503
Study 26699193 — intervention group
Group type: EXPERIMENTAL
Intervention: IUP > 300 MU
Number of subjects: 503
Study 26699193 — intervention group
Group type: COMPARATOR
Intervention: Internal tocodynamometry
Number of subjects: 503
Study 26699193 — intervention group
Group type: EXPERIMENTAL
Intervention: IUP
Number of subjects: 503
Study 24988413 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet (6-7 MJ/day; 35% protein, 4% carbohydrate, 61% fat)
Number of subjects: 76
Study 24988413 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 76
Study 24988413 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric high-carbohydrate, low-fat (HC) diet
Number of subjects: 76
Study 22639013 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g of sodium
Number of subjects: 360000
Study 22639013 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8 g of sodium
Number of subjects: 360000
Study 22639013 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake <4.5 g/day
Number of subjects: 360000
Study 22639013 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake >4.5 g/day
Number of subjects: 360000
Study 22639013 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake 2.5 to 6.0 grams/day
Number of subjects: 360000
Study 19224430 — intervention group
Group type: EXPERIMENTAL
Intervention: PIO (45 mg) + placebo
Number of subjects: 125
Study 19224430 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMVA (40 mg) + placebo
Number of subjects: 125
Study 19224430 — intervention group
Group type: EXPERIMENTAL
Intervention: PIO + SIMVA
Number of subjects: 125
Study 19224430 — intervention group
Group type: COMPARATOR
Intervention: All treatment arms (PIO, SIMVA, PIO + SIMVA)
Number of subjects: 125
Study 19224430 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 125
Study 17568648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient VEP in response to isoluminant chromatic (L-M) sinewave gratings
Number of subjects: 49
Study 15209970 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative thermal sensory testing using Medoc sensory analyzer with copper rods preheated to 40, 43, 46, and 49 degrees C
Number of subjects: 40
Study 15209970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure testing with a 1.25-inch diameter commercially available pressure transducer gauge
Number of subjects: 40
Study 11602545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation during hospital stay
Number of subjects: 17944
Study 11602545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 17944
Study 10206302 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative genomic hybridization (CGH)
Number of subjects: 23
Study 7614520 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg (titrated up to 40 mg) once in the evening
Number of subjects: 168
Study 7614520 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 168